Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Steward Partners Investment Advisory LLC cut its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 22.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,610 shares of the biotechnology company’s stock after selling 741 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Blueprint Medicines were worth $228,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Covestor Ltd grew its holdings in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares in the last quarter. S&CO Inc. grew its holdings in shares of Blueprint Medicines by 49.3% in the third quarter. S&CO Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $925,000 after acquiring an additional 3,300 shares in the last quarter. Swiss National Bank grew its holdings in shares of Blueprint Medicines by 1.6% in the third quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock valued at $10,748,000 after acquiring an additional 1,800 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in shares of Blueprint Medicines by 11.6% in the third quarter. Segall Bryant & Hamill LLC now owns 141,622 shares of the biotechnology company’s stock valued at $13,100,000 after acquiring an additional 14,668 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Blueprint Medicines in the third quarter valued at approximately $475,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their target price on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Scotiabank initiated coverage on Blueprint Medicines in a report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Stephens reissued an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, StockNews.com lowered Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $125.21.

Blueprint Medicines Stock Down 0.3 %

NASDAQ BPMC opened at $89.58 on Friday. The business’s 50-day moving average is $99.54 and its 200 day moving average is $94.02. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The stock has a market capitalization of $5.72 billion, a PE ratio of -82.94 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Buying and Selling

In other Blueprint Medicines news, insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the sale, the insider now owns 14,967 shares of the company’s stock, valued at approximately $1,496,700. The trade was a 13.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,608 shares of company stock worth $4,668,161 in the last three months. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.